Eli Lilly and Company

🇺🇸New York Stock Exchange
Back to all articles
Eli Lilly and Company stock analysis LLY overview
Bullish +65

FDA Approves New Eight-Week Maintenance Dosing Regimen for Eli Lilly’s (LLY) EBGLYSS

📅 FDA approved an eight-week maintenance dosing regimen for Eli Lilly's EBGLYSS on June 9.

👥 The new regimen applies to adults and children aged 12 and older with moderate-to-severe atopic dermatitis.

💉 Patients can now receive a single injection once every 8 weeks instead of more frequent dosing.

🏆 EBGLYSS becomes the only treatment option manageable with as few as six maintenance injections per year.

🚫 The new regimen does not require concomitant prescription topicals for maintenance.

📊 Approval is based on data from the Phase 3 ADjoin long-term extension trial covering 32 weeks.

✅ Clinical data showed durable disease control without new safety signals or discontinuations due to adverse events.

🛡️ Common side effects remain consistent with the existing profile including conjunctivitis and injection site reactions.

👩‍⚕️ Management noted the regimen reduces the burden of daily symptom management for patients.

💊 EBGLYSS is a human pharmaceutical product developed by Eli Lilly in the immunology space.

Bullish Signals
  • FDA approval of an extended dosing interval simplifies patient treatment regimens and improves convenience.
  • EBGLYSS becomes the only atopic dermatitis treatment requiring as few as six injections per year without topicals.
  • Long-term extension trial data confirms durable disease control over 32 weeks with no new safety signals.
  • No patients discontinued the drug due to adverse events in the long-term study, supporting its safety profile.
  • The regimen reduces the burden of daily symptom management and frequent injections for patients.
Full Analysis
On June 9, the US FDA approved a new eight-week maintenance dosing regimen for Eli Lilly's (LLY) EBGLYSS (lebrikizumab-lbkz). This approval allows adults and children aged 12 and older with moderate-to-severe atopic dermatitis to receive a single injection once every eight weeks, reducing the frequency from the previous schedule. EBGLYSS becomes the only treatment option capable of managing the condition with as few as six maintenance injections per year without requiring concomitant prescription topicals. The dosing update is based on longitudinal exposure-response modeling and data from the Phase 3 ADjoin long-term extension trial, which involved a 32-week study period. Clinical data from the extension study demonstrated durable disease control with no new safety signals or patient discontinuations due to adverse events. Management highlighted that this regimen provides significant flexibility for patients aiming to reduce the burden of daily symptom management and frequent injections. The most commonly reported side effects remain consistent with the existing profile, including conjunctivitis, injection site reactions, and herpes zoster. This regulatory milestone reinforces EBGLYSS's position in the atopic dermatitis market by offering a convenient long-term maintenance option that eliminates the need for daily topical therapies. The approval expands the drug's utility and convenience factor, potentially influencing prescribing patterns and patient adherence in the competitive landscape of skin disease treatments.